Belvarafenib

DRUG3 trials

Sponsors

Hoffmann-La Roche, Genentech, Inc., Hanmi Pharmaceutical Company Limited

Conditions

Advanced or Metastatic MelanomaMelanomaSolid Tumors

Phase 1

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Active, not recruitingNCT04835805

Genentech, Inc.Melanoma

Start: 2021-05-13End: 2027-06-30Updated: 2026-03-30

Phase 2

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Active, not recruitingNCT04589845

Hoffmann-La RocheSolid Tumors

Start: 2021-01-18End: 2032-09-25Target: 920Updated: 2026-04-02

Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma

RecruitingNCT07449754

Hanmi Pharmaceutical Company LimitedAdvanced or Metastatic Melanoma

Start: 2026-02-12End: 2030-03-01Target: 45Updated: 2026-03-04

Related Papers

Efficacy and safety of pralsetinib in <i>RET</i> fusion-positive solid tumors: Data from the TAPISTRY trial.

Journal of Clinical Oncology2026-01-10

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

2026-01-09

Updated efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring <i>ROS1</i> fusions.

Journal of Clinical Oncology2025-05-28

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.

2025-04-075 citations

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

European Journal of Cancer2025-02-224 citations

TRLS-12. EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITH<i>NTRK</i> OR<i>ROS1</i> FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS

Neuro-Oncology2024-06-18

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.

Journal of Clinical Oncology2024-06-051 citations

Ipatasertib in patients with <i>AKT1/2/3</i> mutation-positive (<i>AKT</i>mut) tumors: TAPISTRY study.

Journal of Clinical Oncology2024-06-014 citations

Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring <i>NTRK</i> or <i>ROS1</i> fusions.

Journal of Clinical Oncology2024-06-012 citations

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

JNCI Journal of the National Cancer Institute2024-05-069 citations

Abstract CT265: Trastuzumab emtansine in patients (pts) with <i>HER2</i> mutation-positive <i>(HER2</i>mut<i>)</i> tumors: TAPISTRY study

Cancer Research2024-04-05

Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic <i>NTRK</i> fusion-positive (<i>NTRK</i>-fp) solid tumors.

Journal of Clinical Oncology2022-06-0130 citations

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours

BMJ Open2022-05-0113 citations

Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial

ESMO Open2021-11-1910 citations

Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial.

Journal of Clinical Oncology2021-05-2011 citations